The news is directly related to Pharvaris as Morgan Stanley has reiterated its Equal-Weight rating on the company and maintained its price target. This suggests that the analyst sees the stock as fairly valued at its current price, which could influence investor sentiment and trading behavior. However, as this is a reiteration of a previous rating and price target, it may not have a significant impact on the stock's price in the short term.